2024
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, Dickinson M, Prica A, Major A, Hendrickson P, Hopkins D, Ng A, Casulo C, Baron J, Roberts K, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin L, Henry M, Smith C, Halperin D, Brady J, Brennan B, Senchenko M, Reeves M, Hoppe B, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes E, Lee D, Doo N, Barraclough A, Cheah C, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer M, Eichenauer D, Hoppe R, Borchmann P, Fuchs M, Hartmann S, Eich H, Lo A, Skinnider B, Rauf M, Maghfoor I, Pinnix C, Milgrom S, Vega F, Alomari M, Collins G, Advani R, Metzger M, Wirth A, Tsang R, Smith S, Kelsey C, McKay P, Koenig J, Constine L, Sakthivel K, Plastaras J, Gao S, Al Rahbi N, Levis M, Sridhar A, Shah N, Osborne W, Chang I, Miall F, Mikhaeel G, Penn A, Volchkov E, Della Pepa R, Northend M, Opat S, Salvaris R, Tedjaseputra A, Palese M, Shankar A, Natkunam Y, Kelly K. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal Of Clinical Oncology 2024, 42: 2271-2280. PMID: 38531001, DOI: 10.1200/jco.23.01655.Peer-Reviewed Original ResearchNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalLymphocyte-predominant Hodgkin lymphomaInternational Prognostic ScoreImmunoarchitectural patternsOverall survivalHodgkin lymphomaPrognostic scoreSplenic involvementAssociated with worse progression-free survivalAssociated with progression-free survivalDe-escalation of therapyMedian follow-upAge of patientsProspective clinical trialHigh-risk patientsStage III-IVClinical risk factorsRisk of transformationStage I to IIB symptomsAdult patientsIII-IVActive surveillanceRare cancers
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIBPediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL management
2017
CNS Leukemia
An Y, Roberts K. CNS Leukemia. 2017, 311-333. DOI: 10.1007/978-3-319-55430-3_17.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute lymphoblastic leukemiaAllogeneic stem cell transplantCentral nervous system involvementPediatric acute lymphoblastic leukemiaInduction systemic therapyHigh-risk patientsNervous system involvementTotal body irradiationStem cell transplantUse of radiotherapyHigh cure ratesIntensity of therapyBlood-brain barrierCNS leukemiaCNS relapseCNS lymphomaPalliative therapySystemic therapyPrognostic factorsBody irradiationCell transplantRisk stratificationCure rateCommon cancer